Metagenomi Therapeutics Price to Free Cash Flow Ratio 2022-2025 | MGX
Historical price to free cash flow ratio values for Metagenomi Therapeutics (MGX) since 2022.
| Metagenomi Therapeutics Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-02-18 | 1.47 | 0.00 | |
| 2025-09-30 | 2.37 | $-2.83 | 0.00 |
| 2025-06-30 | 1.48 | $-3.02 | 0.00 |
| 2025-03-31 | 1.36 | $-2.57 | 0.00 |
| 2024-12-31 | 3.61 | $-3.40 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.055B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.071B | 12.09 |
| BridgeBio Pharma (BBIO) | United States | $14.501B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.806B | 18.36 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.915B | 23.87 |
| Bausch Health Cos (BHC) | Canada | $2.222B | 1.58 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.310B | 9.44 |
| Taysha Gene Therapies (TSHA) | United States | $1.246B | 0.00 |
| Personalis (PSNL) | United States | $0.729B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.422B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.187B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |